Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (August 2025)
9 slides from Alzecure Pharma Ab's investor presentation, Aug 27, 2025
Slide 1: Orphan Drug Market - Past, Present & Future
Orphan Drug Market - Past, Present & Future Dimitrina Dimitrova Master in Bioentrepreneurship Karolinska Institutet dimitrina.chukova@stud.ki.se dimitrina-dimitrova@outlook.com
Slide 2: Understanding Orphan and Rare Diseases
Understanding Orphan and Rare Diseases Rare Disease Orphan Drug Ultra - Orphan Drug US < 200 , 000 people nationwide . ¹ A medicine developed specifically to US fewer than 6 , 000 patients . treat a rare disease, granted special EU < 5 in 10 , 000 people in the population . ² incentives to encourage
Slide 3: Orphan Market Size
Orphan Market Size $195.2 Billion1 60% US2 2x Higher CAGR1 1. EvaluatePharma. World Preview 2024, Outlook to 2030. 2024. 2. Grand View Research. Global Pharmaceutical Market Report 2025–2030. 2025.
Slide 4: Investing in Small Patient Populations: Orphan Incentives
Investing in Small Patient Populations Orphan Incentives Reaching Market Additional FDA Legislative Wins Patients Sooner Exclusivity Support Long market exclusivity (7–10 years Orphan Drug Act (1983) Time to market ~5 yrs (vs. 10–12) Dedicated Orphan Products Unit US/EU) 2025 Bill expanded protectio
Slide 5: Big Orphan Pharma
Big Orphan Pharma Global Pharma Revenue1 >50% Sales2 20% Premium Pricing3 17x 1. FDA – Orphan Pharma Report, 2025 2.EMA – Orphan designation: Overview, 2024 3.IQVIA Institute. Global Trends in Orphan Drug Pricing. 2022.
Slide 6: HealthCap: Active Swedish Investor in Orphan Companies
HealthCa Active Swedish Investor in Orphan Companies Wilson’s disease (ultra - rare) ~$86-123M 8 Companies ~10,000 – 30,000 patients worldwide In 6 years - USD 855 million Wilson Therapeutics 2 acquisition 1. HealthCap. Portfolio. 2024. 2.Alexion. Alexion to Acquire Wilson Therapeutics AB. Press Rel
Slide 7: The Future: Precision Medicine & Orphan Drugs
The Future: Precision Medicine & Orphan Drugs Targeted Treatments Genomic, environmental & lifestyle data Enhanced Diagnostics Gender, age, disease progression, genetic makeup
Slide 8: Key Insights
3 Key Insights Big Pharma Orphan drugs are the They are shaping the dominance & fastest-growing future of precision premium pricing segment in Pharma. medicine. drive strong investment value.
Slide 9: Thank you!
Thank you! Dimitrina Dimitrova Master in Bioentrepreneurship Karolinska Institutet dimitrina.chukova@stud.ki.se dimitrina-dimitrova@outlook.com Weblink: https://sites.google.com/view/orphandrugreport2025/home
AlzeCure Pharma — Investor Presentation (August 2025) on 6ix